Compare WTM & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTM | TVTX |
|---|---|---|
| Founded | 1980 | N/A |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.7B |
| IPO Year | 1994 | 2013 |
| Metric | WTM | TVTX |
|---|---|---|
| Price | $2,376.30 | $52.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $75.14 |
| AVG Volume (30 Days) | 17.3K | ★ 2.1M |
| Earning Date | 11-17-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.04% | N/A |
| EPS Growth | ★ 379.05 | 92.89 |
| EPS | ★ 67.36 | N/A |
| Revenue | ★ $3,735,000,000.00 | N/A |
| Revenue This Year | N/A | $55.24 |
| Revenue Next Year | N/A | $43.78 |
| P/E Ratio | $33.87 | ★ N/A |
| Revenue Growth | ★ 66.76 | N/A |
| 52 Week Low | $1,870.00 | $22.59 |
| 52 Week High | $2,349.36 | $68.73 |
| Indicator | WTM | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 66.56 | 33.18 |
| Support Level | $2,092.37 | $41.75 |
| Resistance Level | $2,320.75 | $59.93 |
| Average True Range (ATR) | 47.04 | 2.58 |
| MACD | 10.00 | 0.17 |
| Stochastic Oscillator | 65.73 | 43.17 |
White Mountains Insurance Group Ltd is engaged in the business of making opportunistic and value-oriented acquisitions of businesses and assets in the insurance, financial services, and related sectors, operating these businesses and assets through its subsidiaries and, if and when attractive exit valuations become available, disposing of these businesses and assets. The company conducts its business in five areas: property and casualty insurance and reinsurance, municipal bond reinsurance, capital solutions for asset and wealth management firms, property and casualty insurance distribution, and other operations. The company has four reportable segments: Ark/WM Outrigger, HG Global, Kudu and Distinguished.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.